announced today that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada to Hikma Pharmaceuticals’ KLOXXADO ® (naloxone HCl) Nasal Spray, an 8 mg ...

Hikma will continue producing its 8 mg naloxone HCl nasal spray in its Columbus, Ohio manufacturing facility and will provide it to Emergent as its exclusive commercial partner. "We are thrilled ...

The nasal spray, called Neffy ... "For people who are on commercial insurance, the cost is going to be limited to about $25," Gounder said. "And then for people who are underinsured or uninsured ...

ARS Pharmaceuticals chief commercial officer Eric Karas stated ... In 2024, ALK-Abelló acquired the rights to neffy adrenaline nasal spray in Europe and Canada, amongst other regions, from ...

PharmAla Biotech (CSE:MDMA) issued a public warning after discovering that unknown parties are illegally marketing a nasal ...

The event will detail the commercial strategy for etripamil nasal spray (proposed trade name CARDAMYST™), showcasing the company's focus on innovation in its product offerings for managing ...

“The availability of epinephrine nasal spray may reduce barriers to rapid ... For people with severe allergic reactions who have commercial insurance that covers Neffy, ARS said it will use ...

An alternative, nasal spray, formulation has been developed that demonstrates good efficacy, high tolerability and a very fast onset of action. This study assessed the pharmacokinetics and ...

at $25 for most people with commercial insurance and $199 for people with high-deductible plans or no insurance. The nasal spray has a shelf life of about two and a half years, which means ...

The nasal route offers a number of benefits over some of the traditional routes of administration for biologics.

Jan. 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada to Hikma ...